About Us

Introduction

Founded by the top-notch biologist Dr. Yi Rao in 2019, Gritgen is dedicated to make "Great Science for human health" and committed to becoming a global biotech by innovative research.

2019

Founded in
3

Site
8600sq.m.

cGMP
3

Technology Platform

Mission

Great Science for Human Health

Vision

Innovative gene therapy better the lives of all mankind

Value

Seeking Truth
Excellence
Cooperation
Responsibility

History

2023
2022
2021
2020
2019

2023
2022
2021
2020
2019

2023
2022
2021
2020
2019

- January
  GS1191, a gene therapeutic product for hemophilia A totally developed by Gritgen, has got IND approval and initiated Phase I trials in P.R. China.
- January
  Gritgen raised RMB 300 million for series A financing.
- December
  The cGMP commercial manufacturing facility was completed.
- March
  Patient enrollment was initiated for the investigator initiated trial (IIT) of GS1191.
- May
  The Gritgen headquarters moved to suzhou industrial park.
- December
  Gritgen raised RMB 80 million for series pre-A financing.
- September
  Gritgen Therapeutics was founded in Beijing.

Team Introduction

Founders
- Yi Rao, Ph.D.
  
  Scientific Founder & Chairman of Scientific Advisory Board
  
  Dr. Yi Rao was fully involved in the establishment and management of Gritgen, and provided scientific guidance for Gritgen.
  
  Dr. Yi Rao has involved in the reform and construction of many scientific and educational institutions in China. He assisted the Chinese Academy of Sciences to establish the Institute of Neuroscience in Shanghai and participated in the establishment of the National Institute of Biological Sciences in Beijing. He founded or co-founded the Shanghai Interdisciplinary Research Center of the Chinese Academy of Sciences, the Peking University-Tsinghua University Joint Center for Life Science, the Peking University McGovern/IDG Brain Institute, and the Beijing Institute of Life Sciences. He is one of the co-sponsors of West Lake University and the former director of its Institute of Basic Medicine. He was one of the scientists that founded China's "Future Science Prize" and a co-sponsor of the "Science Discovery Award".
  He is a member of the Medical Board of the Canadian Gairdner International Medical Awards.
  Dr. Yi Rao got his Ph.D. degree in neuroscience from the University of California, San Francisco. He was a postdoctoral fellow in the Department of Biological Chemistry and Molecular Biology at Harvard University.
- Jianjin Dong, M.L.
  
  Founder & Chairman
  
  Chairman of Gritgen
  
  Before establishing Gritgen, Jianjin Dong engaged in the law practice in the financial market for nearly 20 years and served as the executive director of a top international financial institution and the chief lawyer of Shanghai International Energy Exchange Co., Ltd.
  Jianjin Dong has extensive experience in the financial market and has provided legal advice to several financial regulators and self-regulated organizations.
Co-founders
- Fenglan Wu, Ph.D.
  
  Co-founder & CEO
  
  Responsible for overall corporate strategy and the Company's comprehensive operation management
  
  Dr. Wu has a profound industrial and financial background in the pharmaceutical field and has practical experience in pharmaceutical R&D, company operation, and financial marketing for over 10 years.
  Dr. Wu was formerly served as the Research scientist at GSK, senior scientist at Zai Lab, and vice president of China Renaissance.
  Ph. D. Pharmacy Shanghai Jiao Tong University,
  Master Immunology Shanghai Jiao Tong University,
  Bachelor Pharmacy Tongji Medical College.
- Tenghui Yu, Ph.D.
  
  Co-founder & Vice President, Discovery
  
  Responsible for drug early discovery and development
  
  Dr. Yu has deep understanding on the drug early discovery, AAV vector development and clinical translation .
  Postdoctoral fellow Peking University,
  Ph. D. Physiology Peking University,
  Bachelor Biological Sciences Sun Yat-sen University.
Senior Executives
- Claire Zhang, Ph.D.
  
  Co-founder & CTO
  
  Responsible for the Company's CMC
  
  Dr. Zhang has more than 30 years of experience in the field of CMC of original new drug.
  Dr. Zhang has led the large-scale production of gene therapy products using the most advanced technology in the United States.
  She received her PhD in molecular biology from University of Paris and her bachelor's degree in biochemistry from Nanjing University.
- Changdong Liu, Ph.D.
  
  CMO
  
  Responsible for the clinical development and registration of the Company's pipelines
  
  Dr. Liu is a senior clinician and scientist.
  He possesses over 40 years of extensive expertise in the fields of original new drug development, clinical trials, regulatory affairs, and ophthalmic clinical practice across China and the United States.
  He received a postdoctoral fellowship from the University of Pennsylvania and an MD from Tongji Medical University in Wuhan.
- Qingliang Zhang
  
  CFO
  
  Responsible for the Company's financial management
  
  Ms. Zhang has worked at investment bank for nearly ten years and possesses rich experience in investment and financing and capital market operation.
  Ms. Zhang has worked at investment bank for nearly ten years and possesses rich experience in investment and financing and capital market operation.
  She received her dual master's degree in electronic engineering & artificial intelligence and bachelor's degree in electronic engineering from University of Cambridge.

Founders
Co-founders
Senior Executives